Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Other financing activities (2018 - 2022)

Editas Medicine (EDIT) has disclosed Other financing activities for 5 consecutive years, with $367000.0 as the latest value for Q2 2022.

  • On a quarterly basis, Other financing activities fell 30.23% to $367000.0 in Q2 2022 year-over-year; TTM through Jun 2022 was $1.5 million, a 0.33% change, with the full-year FY2022 number at $979000.0, down 15.02% from a year prior.
  • Other financing activities was $367000.0 for Q2 2022 at Editas Medicine, down from $526000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $526000.0 in Q2 2021 to a low of $100000.0 in Q1 2018.
  • A 5-year average of $331333.3 and a median of $356000.0 in 2018 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: skyrocketed 50.29% in 2021, then crashed 30.23% in 2022.
  • Editas Medicine's Other financing activities stood at $362000.0 in 2018, then decreased by 21.82% to $283000.0 in 2019, then rose by 23.67% to $350000.0 in 2020, then surged by 50.29% to $526000.0 in 2021, then plummeted by 30.23% to $367000.0 in 2022.
  • Per Business Quant, the three most recent readings for EDIT's Other financing activities are $367000.0 (Q2 2022), $526000.0 (Q2 2021), and $350000.0 (Q2 2020).